CD44 and breast carcinoma: Additionally, tumors treated with sequential paclitaxel and epirubicin-based chemotherapy showed an enrichment of ALDH+ tumor cells with no significant changes in CD44+/CD24− populations [95], further suggesting distinct stem cell populations may exist within breast cancer tumors and may contribute to drug resistance.